Literature DB >> 14575844

How low is the alpha/beta ratio for prostate cancer?

Henk B Kal1, Marion P R Van Gellekom.   

Abstract

PURPOSE: Recently, low alpha/beta values of 1.2 and 1.5 Gy for prostate tumors have been derived from clinical results of external beam radiotherapy and of permanent implants of (125)I and (103)Pd. In the analyses the contributions of tumor repopulation, and edema as a result of inserting radioactive seeds in the prostate, have been ignored. In this paper we reanalyzed the clinical data and introduced the contribution of repopulation and edema. METHODS AND MATERIALS: The linear quadratic-biologically effective dose model was used for reanalysis. In this model, the influence of repopulation and edema has been taken into account. The biologically effective dose was calculated as a function of alpha/beta for 2 brachytherapy regimens with (125)I and (103)Pd and 2 fractionated treatments, and for different half-times for repair of sublethal damage for the brachytherapy regimens.
RESULTS: We have found a plausible alpha/beta value of 3.1 to 3.9 Gy, an alpha value of 0.1 to 0.15 Gy(-1), and a half-time of repair of about 0.5 h.
CONCLUSIONS: It seems now that the alpha/beta value is low, 3.1-3.9 Gy, but not as low as the 1.2 and 1.5 Gy reported earlier.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575844     DOI: 10.1016/s0360-3016(03)01455-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

1.  Dosimetric effect of intrafraction motion and residual setup error for hypofractionated prostate intensity-modulated radiotherapy with online cone beam computed tomography image guidance.

Authors:  Justus Adamson; Qiuwen Wu; Di Yan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-18       Impact factor: 7.038

2.  Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing.

Authors:  Quentin Adams; Karolyn M Hopfensperger; Yusung Kim; Xiaodong Wu; Weiyu Xu; Hemant Shukla; James McGee; Joseph M Caster; Ryan T Flynn
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-08-06       Impact factor: 7.038

3.  Mechanistic modelling of prostate-specific antigen dynamics shows potential for personalized prediction of radiation therapy outcome.

Authors:  Guillermo Lorenzo; Víctor M Pérez-García; Alfonso Mariño; Luis A Pérez-Romasanta; Alessandro Reali; Hector Gomez
Journal:  J R Soc Interface       Date:  2019-08-14       Impact factor: 4.118

4.  CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed.

Authors:  B Detti; P Bonomo; L Masi; R Doro; S Cipressi; C Iermano; I Bonucci; D Franceschini; L Di Brina; M Baki; G Simontacchi; I Meattini; M Carini; S Serni; G Nicita; L Livi
Journal:  World J Urol       Date:  2015-06-11       Impact factor: 4.226

5.  Evaluation of Biological Effective Dose in Gamma Knife Staged Stereotactic Radiosurgery for Large Brain Metastases.

Authors:  Taoran Cui; Joseph Weiner; Shabbar Danish; Anupama Chundury; Nisha Ohri; Ning Yue; Xiao Wang; Ke Nie
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

6.  Choline PET based dose-painting in prostate cancer--modelling of dose effects.

Authors:  Maximilian Niyazi; Peter Bartenstein; Claus Belka; Ute Ganswindt
Journal:  Radiat Oncol       Date:  2010-03-18       Impact factor: 3.481

7.  Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells.

Authors:  Weiwei Xiao; Peter H Graham; Jingli Hao; Lei Chang; Jie Ni; Carl A Power; Qihan Dong; John H Kearsley; Yong Li
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

8.  The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer.

Authors:  Beata Smolska-Ciszewska; Leszek Miszczyk; Brygida Białas; Marek Fijałkowski; Grzegorz Plewicki; Marzena Gawkowska-Suwińska; Monika Giglok; Katarzyna Behrendt; Elżbieta Nowicka; Aleksander Zajusz; Rafał Suwiński
Journal:  Radiat Oncol       Date:  2015-03-07       Impact factor: 3.481

9.  Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer.

Authors:  Jasper Yuen; George Rodrigues; Kristina Trenka; Terry Coad; Slav Yartsev; David D'Souza; Michael Lock; Glenn Bauman
Journal:  Radiat Oncol       Date:  2008-01-07       Impact factor: 3.481

Review 10.  Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits.

Authors:  K J Ray; N R Sibson; A E Kiltie
Journal:  Clin Oncol (R Coll Radiol)       Date:  2015-03-07       Impact factor: 4.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.